

## MESSAGE from the President

As an industry, we contribute significantly to the Puerto Rican economy. For more than four decades we have pushed the bar higher and created a robust ecosystem for the biotechnology, pharmaceutical and medical device sectors. We are professionals driven by innovation, knowledge, and operational excellence; but it is our team work that has allowed us to drive our industry forward and positively impact as many lives as we do throughout the world.

We face numerous challenges today, but we are trained to overcome adversity. It has never been more important for us to leverage our training along with the talent and capabilities of our people to ensure that we continue impacting society in a positive way; it has never been more important for us to work together.

*Robert Maroney*



## GSK Puerto Rico José A. Naranjo as Sales Director



José A. Naranjo has been appointed Sales Director at GSK Puerto Rico, reporting to Yvonne McBurney, VP and General Manager, effective April 2015. In this role he will be responsible for leading and coaching the Puerto Rico Sales team while effectively executing the PR Commercial strategy.

After successfully completing an MBA Summer Internship with GSK, Naranjo joined GSK in 2002 as part of the Management Development Program. He then held several positions in the US and the UK including: Product Manager, Valtrex Marketing (US Pharma), Global Product Strategy Manager (GSK Global), CV/Metabolic Center of

Excellence European Marketing Manager (Pharma-Europe) and Global Commercial Lead, Standalone Innovation Dermatology Franchise (Global Stiefel Business). His most recent role was Chief of Staff, US Stiefel Business Unit in US-Pharma with responsibility for Sales & Marketing Operations, Business Improvement and Market Research.

Naranjo holds an MBA from the University of North Carolina - Kenan Flager Business School and a Ph.D. in Tax Law from the Universidad Complutense/UNED de Madrid.

## CALENDAR OF EVENTS

# JUNE

13<sup>TH</sup> Annual PIA-PR Regulatory Conference  
Ritz-Carlton Hotel-San Juan, PR  
To register : visit [piapr.org](http://piapr.org)

SU	MO	TU	WE	TH	FR	SA
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30				

## GSK completes major three-part transaction with Novartis

Issued: London UK - LSE Announcement

GlaxoSmithKline plc (LSE/NYSE: GSK) announced that its three-part transaction with Novartis was completed in March. As a result of this transaction GSK has:

- Acquired Novartis's global Vaccines business (excluding influenza vaccines) for an initial cash consideration of **\$5.25 billion**;
- Created a new world-leading Consumer Healthcare joint venture with Novartis in which GSK will have majority control and an equity **interest of 63.5%**; and
- Divested its Oncology business for an aggregate cash consideration of **\$16 billion**.

The net after tax proceeds of the transaction received by GSK are estimated to be **\$7.8 billion**. This reflects the full consideration of **\$16 billion** paid by Novartis for GSK's Oncology portfolio and related assets.

Under the terms of the transaction, up to **\$1.5 billion** of that purchase price may have to be returned to Novartis if certain conditions relating to the COMBI-d Trial are not met. Following the positive results from this study announced on February 6 2015, GSK believes these conditions will be satisfied.

Sir Andrew Witty, GSK, CEO said: "Completion of this transaction represents a major step forward in the Group's strategy to create a stronger and more balanced set of businesses across Pharmaceuticals, Consumer Healthcare and Vaccines. We will now be focused on rapidly implementing our integration plans to realize the growth and synergy opportunities we see in the new Consumer Healthcare and Vaccines businesses."

## GSK/Novartis transaction



## abbvie INVESTS \$30 MILLION

AbbVie will invest **\$30 million** in a two-year expansion in Barceloneta and is **expected to create 100 jobs**, announced **Néstor Ortiz de Hoyos, director of government affairs for AbbVie Puerto Rico**. The biological plant produces Humira, an anti-inflammatory drug which is a major revenue

producer for the Company. As a research-based biopharmaceutical company, AbbVie employs 25,000 people throughout its 13 plants worldwide. The Company sells biologics in more than 170 countries.

## Amgen BioTalents and UPR bet on talented students for Puerto Rico's Bio Industry

Amgen and the University of Puerto Rico, Mayaguez campus (UPRM), will continue to work jointly in the **"Amgen BioTalents"** training program to strengthen the industrial-manufacturing area by fostering the leadership, supervision skills and capabilities of science and engineering students. The program will impact **180** local students majoring in biology, microbiology, chemistry, industrial biotechnology and engineering over a three-year period.

The Amgen Biotechnology Training and Learning Enhancement for Students program (**"Amgen BioTalents"**) is a pioneering initiative in Puerto Rico that provides an interdisciplinary, internship-like experience and brings students in contact with equipment that replicates the real-life systems used in live sciences manufacturing facilities.

The program is free of cost to participating students. "The University of Puerto Rico puts its best talents to work for Puerto Rico," said Uroyoán R. Walker Ramos, president of UPR. **"The Amgen BioTalents program** is one more example of the trust in UPR's capacity and commitment to developing the talent Puerto Rico and the world needs. For these talented young people, participating in this project represents an opportunity to grow, gain knowledge and develop themselves in the biosciences field, one of the areas of greatest competition and demand," said Walker Ramos.

Robert Maroney, operations vice-president for Amgen in Puerto Rico, said "these experiences help contribute to develop a generation of young science, industrial biotechnology and engineering professionals with the knowledge,

and also with the motivation and passion to build a successful career thanks to the access to unique resources and experiences not found in a traditional educational curriculum." Maroney added that the main objective of the **"Amgen BioTalents"** program is to promote the development of a new generation of highly trained professionals who will have the tools needed to drive and sustain an economic culture based on scientific knowledge and leadership in Puerto Rico.

Dr. Rosa Buxeda, a UPRM professor and academic senator who leads the "Amgen BioTalents" program, said that 43 percent of the 180 students are currently completing their BA in Science and 57 percent (who already have a BA in Science) have applied to a Science graduate program in pursuit of a Masters Degree. "We are deeply satisfied to learn that all students who will pursue a Masters Degree in Science will do so in Biosciences. From this particular group, 40 percent will continue to obtain a PhD degree, while the

remaining 60 percent is already positioned as highly trained personnel ready for hire in the local pharmaceutical industry," said Dr. Buxeda.

The program also includes the **"Amgen BioTechnology Lecture Series"** initiative, through which Amgen associates are invited to offer lectures at UPR Mayaguez. In 2015, the series will be extended to other UPR campuses, such as Rio Piedras, Arecibo and Carolina, and private college campuses as part of an expansion to the academic community in the manufacturing specialized field. To date, the **"Amgen BioTechnology Lecture Series"** has impacted over 1,500 students and professors in Puerto Rico. See more at: <http://www.amgeninspires.com/amgen-biotalents.html#sthash.uYS4vQur.dpuf>

## Lilly del Caribe and United Way of Puerto Rico

United Way of Puerto Rico awarded five recognitions to Lilly del Caribe as part of the 2014 United Way yearly campaign closing event.

- The recognitions are:
- Top Twelve Community Investors - for being among the first 12 companies with the highest amount of collections from employee contributions, corporate matching gifts and special events.
  - Impact Campaign- for significantly increasing collections.
  - MAS Campaign- for the highest level of collections by geographic region.
  - Goal Achievement- for the strategic effort in reaching or surpassing the goal established by United Way.
  - Committee of the Year- for the group of heroes who worked as a team to ensure the success of the campaign.

**Pictured from right: Israel Faberllé, vice president of United Way of Puerto Rico; Carla Amieiro, Cynthia Incarnación and Lynamar Ortiz from Eli Lilly PR; Juan Colón, president of the Campaign Committee of United Way of Puerto Rico, and Samuel González, president of United Way of Puerto Rico.**

